AD/PD 2024: the role of blood-based biomarkers in Alzheimer’s disease
Updated guidelines on the use of biomarkers for Alzheimer's disease are expected to be published later this year.
EMIS Pathway WP
Amylyx considers scrapping ALS drug following Phase III flop
Shifting patterns in cervical cancer cases in women in their 30s and 40s
Pipeline moves: Prospects drop after investigator-led trial of Roche’s Tecentriq terminated
Comorbidities associated with ADHD present an opportunity for pipeline products
The magrolimab trial halt highlights the uncertainties in anti-CD47 immunotherapy
Epetraborole Phase III enrolment pause sets back NTM late-stage pipeline
Pipeline Moves: Approval prospects for ALL candidate rise after Phase III completion
